Navigation Links
Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness
Date:1/14/2014

SAN FRANCISCO, Jan. 14, 2014 /PRNewswire/ -- Spark Therapeutics, a late-stage gene therapy company, has reached its patient recruitment goal for its most advanced clinical program, a Phase 3 study for inherited retinal dystrophies caused by mutations in the RPE65 gene. Spark's CEO, Jeffrey D. Marrazzo, is presenting this and other corporate updates today, at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco. Marrazzo said Spark was able to achieve its recruitment goal a year after the study's initiation and anticipates filing a BLA on the final data in 2015. Currently, there are no pharmacologic treatments for this or any form of inherited retinal dystrophy, which ultimately causes irreversible blindness.

"The fact that we were able to enroll patients in our lead clinical program so quickly and seamlessly reflects the critical, unmet medical need associated with inherited retinal dystrophies as well as the deep expertise of our founders and the hard work of the clinical teams at The Children's Hospital of Philadelphia and the University of Iowa," said Jeffrey D. Marrazzo, co-founder, president and chief executive officer. "In order to realize our vision of transforming the lives of patients in a single therapeutic dose, we must continue to operate at the highest standard, as we have in achieving patient recruitment for Phase 3 of our lead candidate right on the heels of our corporate launch."

Spark's patient recruitment goal for the Phase 3 study was a minimum of 24 patients. The open-label, randomized, controlled study builds on a Phase 1/2 clinical trial in which 12 patients with RPE65-related blindness demonstrated notable improvements in functional vision, moving in some cases from being profoundly blind to being able to recognize fa
'/>"/>

SOURCE Spark Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Snoring Therapy Awarded The Prestigious Spark Award
2. Kalyspo Awarded Best of Ann Arbor SPARK Boot Camp
3. Next Generation Sequencing Bioinformatics Heats up: Nearing $1000 Genome Sparks Soaring Data Output
4. Spark Therapeutics to Present at 32nd Annual J.P. Morgan Healthcare Conference
5. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
6. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
8. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
9. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
10. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
11. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... ROCHESTER, N.Y. , July 23, 2014 ... VSCP ), a leading provider of clinical trial ... , 48, has been named president and chief executive ... of Directors in August 2013 and has held the ... October 25, 2013. Dr. Charles E. ...
(Date:7/23/2014)... 23, 2014 Research and Markets ... in Consumer Healthcare by Application, Sensor Type & by ... 2020" report to their offering. ... an increasing momentum for consumer healthcare monitoring and sensing ... consumer healthcare will lessen the healthcare cost of the ...
(Date:7/23/2014)... MOUNTAIN VIEW, Calif. , July 23, ... in translational preclinical research, today unveiled their new logo ... the transformation of Surpass, corporate culture to one where ... customers. This press release comes on the heels of ... added to the Silicon Valley Team:  David Craig, a ...
Breaking Medicine Technology:Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 2Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 3Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 4Sensor Market in Consumer Healthcare (Patient Monitoring, Therapeutic, Handheld and Homecare, & Fitness and wellness) - Analysis & Forecast to to 2013 - 2020 2Sensor Market in Consumer Healthcare (Patient Monitoring, Therapeutic, Handheld and Homecare, & Fitness and wellness) - Analysis & Forecast to to 2013 - 2020 3SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 2SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 3
... Sept. 30, 2011 Haemonetics Corporation (NYSE: ... quarter of its 2012 fiscal year on October 31, ... hold a webcast to discuss and answer questions about ... 31, 2011. Webcast Link: http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=72118&eventID=4204617 ...
... Sept. 29, 2011 Boston Scientific Corporation (NYSE: ... ( NE ural C ardiac T her A ... a prospective, randomized, international clinical feasibility study designed to assess ... heart failure patients.  The study will evaluate 96 patients with ...
Cached Medicine Technology:Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial 2Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial 3Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial 4
(Date:7/23/2014)... Ft. Lauderdale, FL (PRWEB) July 23, 2014 ... and the largest online retailer of nutritional supplements, has ... Supplement Awards. BPI SPORTS , the fastest growing ... the following categories: , Brand of the Year, Best ... of the Year, Protein Powder of the year - ...
(Date:7/23/2014)... syndrome ( FXS ) is a genetic disorder that ... the autistic spectrum, as well as cognitive deficits. It ... and the most common cause of autism. , Now ... published a study that sheds light on ... today (July 23) in the Journal of Neuroscience ...
(Date:7/23/2014)... disorders of obesity and dementia reside in the brain, ... Behavioral Neuroscience. In the paper, researchers make the case ... the brain responsible for memory and learning. Furthermore, treatments ... in reducing certain dementias., "In the struggle to treat ... This is a new way for providers who treat ...
(Date:7/23/2014)... The voice on the recording was low and calm ... he was infected with the human immunodeficiency virus (HIV) that causes ... thing you know I was on the floor flat on my ... hopeful when the recording ended less than 10 minutes later. “Don’t ... because it is just God setting you up for something ...
(Date:7/23/2014)... PA (PRWEB) July 23, 2014 Four ... have been lauded in the latest ranking of the ... Report . Released online today and slated for ... Guide recognizes Allegheny General Hospital (AGH), Forbes Hospital, Saint ... medical centers across multiple clinical specialties. , ...
Breaking Medicine News(10 mins):Health News:Vote Now; BPI SPORTS is Nominated for Eight 2014 Bodybuilding.com Supplement Awards 2Health News:Vote Now; BPI SPORTS is Nominated for Eight 2014 Bodybuilding.com Supplement Awards 3Health News:Study links enzyme to autistic behaviors 2Health News:Study links enzyme to autistic behaviors 3Health News:Targeting the brain to treat obesity 2Health News:Targeting the brain to treat obesity 3Health News:HIV clinic-based audio project emphasizes the power of patient voices 2Health News:HIV clinic-based audio project emphasizes the power of patient voices 3Health News:Four Allegheny Health Network Hospitals Named High Performers by U.S. News 2Health News:Four Allegheny Health Network Hospitals Named High Performers by U.S. News 3
... antidepressant Lexapro permitted by Food and Drug Administration, U.S.// ... FDA to sell escitalopram, a generic immitator of the oral ... drug are retained by the Forest Labs till March 2012 ... This copyright is illogical as per Teva. ,Lundbeck, ...
... that volunteers distributing condoms in the province would no longer ... rates of teenage pregnancies//. The trust said that only authorized ... protection measure. ,"My concern is that child ... commented Dr Dean Marshall, deputy chairman of the BMA's Scottish ...
... statement has said that drug maker Cipla Ltd. has ... nevirapine// that is to be marketed in a tablet ... similar approval for ondansetron in the injection form. ... following chemotherapy or radiation therapy for cancer. The drug ...
... increased blood pressure. But according to a recent study ... in giving them an uninterrupted sleep at the same ... results were presented at the American Thoracic Society International ... person's physical health, and this study shows once again ...
... presented at the American Thoracic Society International Conference, it was ... in lower lung function. The study of 2,112 adolescents ages ... of vitamin D, the recommended amount for this age group. ... low dietary intake of vitamin D (157 IU or less ...
... it was found that amino acid, l-cysteine can prevent ... of the cancers occur// in the mouth, pharynx and ... drinking. This results in a strong exposure of the ... research group of Professor Mikko Salaspuro, University of Helsinki ...
Cached Medicine News:Health News:Sleep Apnea Patients Benefit from Breathing Mask 2Health News:Decreased Vitamin D Intake among Teens Results in Decreased Lung Function 2Health News:Finnish research: Cysteine Chewing Gum as a cure for cancers of the mouth 2
Performa uncemented stem....
Standard Erlanger hip stem....
Stability cemented stem....
Porous foundation 470 series....
Medicine Products: